The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

This trial is testing whether combining the immunotherapy drug camrelizumab with stereotactic body radiotherapy (SBRT) — a very precise, high-dose form of radiation — improves outcomes for people with nasopharyngeal cancer (a cancer behind the nose) that has returned or spread after prior treatment. **You may be eligible if...** - You are 18 years or older - You have histologically confirmed metastatic or recurrent nasopharyngeal carcinoma - You have at least two tumor lesions, one of which can be safely targeted with radiation - You are in reasonably good health (ECOG score 0–2) - Any prior radiation to a target lesion was given at least 6 months ago **You may NOT be eligible if...** - You have only one lesion - Your lesions cannot be safely irradiated - Your general health is too poor to tolerate treatment - You have had recent immunotherapy that conflicts with the study protocol Talk to your doctor to see if this trial is right for you.